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The Enemy of Good?
Making the Most of Highly
Sensitive Troponin Assays*
Lori B. Daniels, MD, MAS
La Jolla, California
“Be not simply good; be good for something.”
—Henry David Thoreau, 1848 (1)
Troponin assays are getting better, so much so, in fact, that
we as clinicians need to similarly evolve in our understand-
ing of how we can use them most effectively. I have observed
medical house staff cast off the significance of elevated
troponin levels in a patient by diagnosing “troponinemia”
and moving on, as if that were an explanation in and of
itself. House staff are not alone in their misunderstanding of
these test results. The ever-improving sensitivity of troponin
assays has engendered skepticism and caused confusion for
many, but the reality is that the modern troponin assays
truly are better than earlier versions. They are providing
accurate and precise information, and are providing it in
abundance.
See page 1906
Early troponin assays, intended to aid in the diagnosis of
acute myocardial infarction, were generally easy to use,
providing simple “yes/no” answers because of their relative
lack of sensitivity. They worked well, and troponins became
an integral part of the universal definition of myocardial
infarction (2). The universal definition also recommends
minimum standards of precision for any troponin assay used
to diagnose myocardial infarction, noting that the assay
should have a coefficient of variation of 10% at the
threshold concentration representing the 99th percentile
upper limit of a normal reference population. As troponin
assays have become more sensitive and precise in accordance
with this mandate, they have improved the early diagnosis
of myocardial infarction (3,4) but have left a lot of confusion
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served on an advisory board for Singulex.in their wake. Most recently, “highly sensitive” troponin
assays have emerged that can, by definition, detect troponin
in more than 50% of the general population. The most
sensitive of these assays can detect troponin in almost
everyone (5). Thus, troponin assays are no longer simple
binary “yes/no” variables but instead need to be interpreted
as continuous variables, and within a greater context, with
an understanding of the interplay of numerous factors such
as age, sex, and renal function, among others.
In addition, now that troponin levels can be measured in
nearly all individuals, they have become attractive candi-
dates to be used for risk stratification in the general
population. Initial studies of highly sensitive troponin assays
in the general population have shown that even minimally
elevated levels carry prognostic value. This was described in
CHS (Cardiovascular Health Study), which involved elderly
community dwellers aged older than 65 years (6), as well as
in 30- to 65-year-olds from the Dallas Heart Study (7) and
in middle-aged 54- to 74-year-old participants from the
general population in the ARIC (Atherosclerosis Risk in
Communities) study (8). Prevalence of detectable troponin
in these studies ranged from 25% in the younger Dallas
population to 66% in the other 2 studies. Together, these
studies taught us that even minimally elevated cardiac
troponin, at levels below the 99th percentile, are associated
with an increased risk of adverse outcomes, including death,
heart failure, and coronary heart disease.
In this issue of the Journal, Eggers et al. (9) extend these
findings with their report on a community-based cohort of
70-year-olds from the PIVUS (Prospective Investigation of
the Vasculature in Uppsala Seniors) study, in which cardiac
troponin was detectable in nearly all subjects. For this study,
highly sensitive cardiac troponin I (cTnI) was measured in
1,004 individuals from Uppsala, Sweden, and a second cTnI
measurement was performed 5 years later in 81% of the
cohort. Participants were followed up for a total of 8 years.
The authors found detectable cTnI levels in 96% of partic-
ipants at baseline and 99% at the 5-year follow-up, and
these levels were independently associated with both all-
cause and cardiovascular mortality. In addition, median
cTnI levels increased over 5 years, and change in cTnI was
also associated with all-cause mortality.
This study (9) is an important addition to the literature
and will help us interpret troponin levels going forward. For
the first time in a community-based cohort, troponin was
detectable in almost all participants. With the prospect of
ubiquitously detectable troponin levels, we need to learn
more about what factors contribute to relative elevations. In
this and previous studies, elevated troponin and changes in
troponin levels were related to several cardiovascular risk
factors (6–8). As consistently shown in community-based
studies, troponin levels positively correlate with age and are
higher in men than in women. This is also consistent with
a recent study which showed that a lower, sex-specific cutoff
is needed to optimally use high-sensitivity troponin assays
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(10). In PIVUS, body mass index (BMI) was associated
with baseline troponin levels but only in analyses that did
not adjust for echocardiographic variables. However, if
troponin is to be used for risk stratification in the commu-
nity, the majority of individuals would be unlikely to have
echocardiograms a priori; it is probably reasonable, there-
fore, to consider BMI as an important covariate when
interpreting troponin levels in this setting. The association
of troponin with BMI in PIVUS is also consistent with
results from both ARIC and the Dallas Heart Study
(although not CHS) (6–8).
There are also several important differences in the current
study (9) compared with previous studies. In ARIC, the
Dallas Heart Study, and CHS (6–8), as well as in a cohort
of 512 diabetic women from the Women’s Health Study
(11), diabetes was associated with higher troponin levels. In
contrast, troponin levels were not associated with diabetes
status in the current study, although as the authors point
out, there were relatively few diabetic participants in
PIVUS, and the study did not use a very sensitive means of
assessing for diabetes. Also in contrast to previous studies,
baseline troponin levels were not associated with renal
function in PIVUS, even though a decline in renal function
over 5 years was associated with a rise in troponin. The
reason for the lack of association here is unclear but is
contrary to established patterns (12). The study also did not
find a significant association between renal function and
mortality outcomes, which is in contrast to our current
understanding of risk factors.
The study by Eggers et al. (9) has some weaknesses and
raises several questions. Although median troponin levels
increased over 5 years, it is unclear from the data presented
the number of individuals who had an increase in troponin
versus the number who had a decrease, and what the
distribution was, although we do know that only 16 partic-
ipants had a decrease of at least 50%. In addition, although
the addition of troponin improved the integrated discrimi-
nation index compared with a model based on traditional
cardiovascular risk factors, it did not significantly improve
the C-statistic. Furthermore, when natriuretic peptides were
included in the baseline model along with traditional
Considerations in Evaluating Troponin Results in the Era of HighlyTable 1 Considerations in Evaluating Troponin Results in the E
Assay-Specific Factors Patient Factors
Troponin T vs. troponin I Age
99th percentile Sex
10% coefficient of variation Body mass index
Renal function
Left ventricular mass
Left ventricular systolic/diastolic function
Chronic cardiovascular disease
(e.g., CAD, valvular disease, CHF)
Baseline troponin levelCAD  coronary artery disease; CHF  congestive heart failure; PE  pulmonary embolism.cardiovascular risk factors, troponin did not significantly
improve any measure of discrimination or reclassification.
Although troponin levels are promising for assessing car-
diovascular risk, other biomarkers may be more powerful
and effective at present. Meanwhile, change in troponin did
not significantly improve any of these metrics either; there-
fore, it is probably premature to conclude that changes in
troponin levels, as currently modeled, can be used to
meaningfully affect cardiovascular risk stratification. Previ-
ous studies have shown that elevated troponin levels in
otherwise healthy individuals are associated more with
incident heart failure than with incident coronary heart
disease (8), so it is notable that heart failure was not
specifically assessed in the current study. It is plausible that
addition of this outcome measure would positively affect the
incremental benefit of troponin. Finally, this community-
based study had only approximately 50% participation. If a
“healthy volunteer” bias is in effect, actual associations
between troponin levels and outcomes may be even stronger
than described here.
Community-based studies such as the current one (9) add
to our collective understanding of how to interpret and
contextualize these sensitive troponin assays that are des-
tined to show up in our clinics, hospital wards, and
emergency departments. Chronic troponin elevations likely
reflect pathophysiology that is distinct from acute elevations
because the former are associated with a higher risk of future
heart failure, whereas troponin in acutely symptomatic
patients carries an associated higher risk of coronary heart
disease events (13). With the new highly sensitive assays,
most patients will have detectable troponin levels, even
“low-risk” patients with chest pain, but most will not be
having, or even be at increased short-term risk for, an acute
coronary syndrome. Understanding the characteristics that
lead to elevated levels is therefore of paramount importance,
and the study by Eggers et al. (9) helps with this. At the
same time, there are limitations to its immediate translation
into practice. At this point, it is not clear that measuring a
single troponin level in otherwise healthy individuals is
indicated, in the absence of symptoms, let alone measuring
serial troponin levels. However, a cogent argument could be
made for acquiring a “baseline” troponin level in individuals
tive TroponinsHighly Sensitive Troponins
Clinical Context
ymptoms (e.g., duration, time of onset, typical vs. atypical)
hysical examination findings (e.g. rales, edema, irregular rhythm)
oncardiac acute diagnoses (e.g., infection, PE, acute renal failure, rhabdomyolysis)
ecent surgery
ital signs (e.g., hypertensive, tachycardic, hypoxemic)
lectrocardiogram
ardiac imaging
ising/falling pattern of troponinSensira of
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cially in the setting of underlying renal or cardiac disease.
Not only would this information aid with risk assessment,
but it could also serve as a critical comparator if the
individual ever presented with acute symptoms. In addition,
because serial troponin levels carry some prognostic impli-
cations, it raises the question of whether high-sensitivity
troponin assays may be useful for monitoring cardioprotec-
tive (or cardiotoxic) therapies. However, the optimal time
interval between troponin measurements, and the optimal
way to assess changing levels, remain questions that the
current study does not answer.
In summary, the study by Eggers et al. (9) informs us about
troponin levels in a community-based setting but has direct
implications for our care of acutely symptomatic patients. With
highly sensitive troponin assays, detectable troponin and acute
Figure 1 Model for Troponin Testing in Acute and
General Settings
The diagram depicts a hypothetical approach to using high sensitivity (hs) tro-
ponin testing in both community-based and acute care settings. *Indicates an
area for future research, including: the utility of establishing a baseline tro-
ponin level, the appropriate subgroups to screen with a baseline troponin level,
the optimal interventions for individuals with detectable troponin at baseline,
and the optimal interval (if any) for repeat testing of troponin.myocardial infarction are no longer interchangeable concepts. yMore and more often we find that we need to evaluate
troponin levels obtained in acute care settings in context,
integrating the specifics of the troponin assay, the patient’s
demographic characteristics and comorbidities, and especially
the acute clinical scenario, including symptoms, electrocardio-
gram findings, vital signs, and the temporal pattern of troponin
levels (Table 1, Fig. 1). The current study adds to our under-
standing of the clinical factors associated with elevated troponin
levels and their long-term significance; so that, as troponin assays
get better, we can get better at interpreting them.
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